Corcept Therapeutics Inc (CORT)
ROE
Obliczenia
|
2022/Q4 (31 gru 2022) |
2022/Q3 (30 wrz 2022) |
2022/Q2 (30 cze 2022) |
2022/Q1 (31 mar 2022) |
2021/Q4 (31 gru 2021) |
2021/Q3 (30 wrz 2021) |
2021/Q2 (30 cze 2021) |
2021/Q1 (31 mar 2021) |
||
|---|---|---|---|---|---|---|---|---|---|
| Zysk netto (ttm) | w tys. USD | 101 418 | 116 870 | 112 733 | 111 844 | 112 512 | 106 453 | 97 607 | 99 411 |
| Kapitał własny | w tys. USD | 501 842 | 473 364 | 442 326 | 407 811 | 375 806 | 540 229 | 522 675 | 510 802 |
| ROE | 20,21% | 24,69% | 25,49% | 27,43% | 29,94% | 19,71% | 18,67% | 19,46% |
2022/Q4 obliczenia
ROE = Zysk netto (ttm) ÷ Kapitał własny
= $101 418K ÷ $501 842K
= 20,21%
Analiza porównawcza
2022/Q4
Nazwa spółki
Symbol
ROE
Corcept Therapeutics Inc
CORT
20,21%
Amphastar Pharmaceuticals Inc
AMPH
17,29%
Arrowhead Pharmaceuticals Inc.
ARWR
-40,98%
Harmony Biosciences Holdings Inc
HRMY
45,05%
Ironwood Pharmaceuticals Inc
IRWD
26,83%
Myriad Genetics, Inc.
MYGN
-12,64%
Pacira BioSciences Inc
PCRX
2,05%
Prestige Consumer Healthcare Inc
PBH
12,47%
Supernus Pharmaceuticals Inc
SUPN
4,42%
Xencor Inc
XNCR
-7,59%